CRGX: the cashflow

MyFinsight

For the quarter ending 2025-06-30, CRGX had $43,366K increase in cash & cash equivalents over the period. -$115,558K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-06-30
Stock-based compensation expense	12,134
Amortization of operating lease right-of-use assets	1,080
Prepaid expenses and other current assets	-316
Other non-current assets	-5,311
Operating lease liabilities	-6,447
Accounts payable	6,533
Impairment of long-lived assets	10,197
Depreciation	712
Accretion on investments in marketable securities	1,478
Accrued restructuring costs	10,646
Accrued expenses and other current liabilities	-8,590
Accrued clinical and research and development expenses	-11,721
Acquired in-process research and development	665
Net cash used in operating activities	-115,077
Proceeds from sales and maturities of marketable securities	241,756
Purchase of property and equipment	481
Purchases of marketable securities	81,687
Purchase of in-process research and development	1,188
Net cash provided by (used in) investing activities	158,400
Proceeds from exercise of stock options	43
Net cash provided by financing activities	43
Net increase (decrease) in cash, cash equivalents and restricted cash	43,366

Unit: Thousand (K) dollars